These findings provide novel insights into the potential of SNX10 as a prognostic marker and therapeutic target for the management of B-ALL, supporting further research into SNX10-modulating therapies that could improve treatment outcomes for patients with B-ALL. This evidence concerns the gene SNX10 and acute lymphoblastic leukemia.